|
|
[Report]
Schering-Plough: PharmaVitae Profile 2005
Published: 2005/12
|
|
 |
|
|
|
Table of Contents
- CHAPTER 1 EXECUTIVE SUMMARY
- Key findings
- Strategic outlook
- Datamonitor's strategic recommendations
- Current positioning: competitive outlook 2004
- Schering-Plough's forecast revenue stream, 2005-10
- Key issues facing Schering-Plough: 2005-10
- CHAPTER 2 GLOBAL COMPANY STRATEGY
- Introduction to Schering-Plough
- Relative Performance of Business Units
- Schering-Plough's Action Agenda
- Assessment of strategic position
- Strengths
- Weaknesses
- Opportunities
- Threats
- Datamonitor's strategic recommendations
- Therapeutic foci
- Growth strategy assessment
- Organic growth
- Partnerships/licensing
- Mergers and acquisitions
- CHAPTER 3 GLOBAL PORTFOLIO AND PIPELINE ANALYSIS
- Therapy area focus in 2004
- Evolution of therapy area focus, 2004-10
- Key growth drivers and resistors of future performance, 2005-10
- Respiratory franchise
- Marketed products
- Clarinex (desloratadine)
- Nasonex (mometasone)
- Claritin (desloratidine)
- Proventil (albuterol sulfate)
- Foradil (formoterol)
- Asmanex (mometasone furoate)
- R&D compounds
- Asmanex/Foradil (mometasone & formoterol)
- Asthma Therapy
- PS 938285
- Respiratory portfolio sales forecasts and forecast revenue growth
- Infectious Disease franchise
- Marketed products
- Intron franchise
- Avelox (moxifloxacin)
- Cipro/Ciprobay (ciprofloxacin)
- R&D compounds
- Noxafil (posaconazole)
- T-3811 (garenoxacin)
- SCH6 (protease inhibitor)
- SCH351125
- Infectious disease portfolio sales forecasts and forecast revenue
growth
- Arthritis, inflammatory and immune disorders (AIID) franchise
- Marketed products
- Remicade (infliximab)
- Elocon (mometasone)
- R&D compounds
- AIID portfolio sales forecasts and forecast revenue growth
- Cardiovascular franchise
- Marketed products
- Integrilin (eptifibatide)
- Zetia /Vytorin
- R&D compounds
- Thrombin Receptor Antagonist (SCH-530348)
- Cardiovascular portfolio sales forecasts and forecast revenue growth
- Oncology franchise
- Marketed products
- Temodar (temozolomide)
- Caelyx (pegylated liposomal doxorubicin hydrochloride)
- R&D compounds
- Onicit (palonosetron)
- Peg-Intron (pegylated interferon alpha-2b)
- Sarasar (lonafarnib)
- Oncology portfolio sales forecasts and forecast revenue growth
- Other products
- Marketed products
- Subutex/ Subuxone (burprenorphine hydrochloride)
- R&D compounds
- Other portfolio sales forecasts and forecast revenue growth
- CHAPTER 4 US STRATEGY, PORTFOLIO AND PIPELINE
- US Company Strategy
- Introduction to Schering-Plough's presence in the US
- US marketing strategy
- US product sourcing strategy
- Strategic Issues
- Mismatch of cost base and long-term assets base
- US Portfolio and pipeline analysis
- US evolution of therapy area focus, 2004-10
- Infectious disease portfolio US sales forecasts and forecast revenue
growth
- Cardiovascular portfolio US sales forecasts and forecast revenue growth
- Respiratory portfolio US sales forecasts and forecast revenue growth
- Oncology portfolio US sales forecasts and forecast revenue growth
- AIID portfolio US sales forecasts and forecast revenue growth
- Other portfolio US sales forecasts and forecast revenue growth
- CHAPTER 5 CORPORATE DEVELOPMENT
- Financial position, 2003-04
- Financial position, 2003-04
- Revenue growth
- Historical assessment of Schering-Plough's profitability, 2000-04
- Cost structure
- 2004 operating cost ratio benchmarking
- Business model clustering according to 2004 cost ratios
- Liquidity, 2000-04
- 2004 growth and investment momentum
- CHAPTER 6 APPENDIX : SUPPORTING DATA
- Exchange rates
- List of Tables
- Table 1: Breakdown of Schering-Plough's ethical sales by therapy area,
2003-04
- Table 2: Breakdown of Schering-Plough's ethical sales by therapy area,
2004-10
- Table 3: Schering-Plough's marketed respiratory portfolio
- Table 4: Leading products in the allergic rhinitis market
- Table 5: Leading product's in the asthma market
- Table 6: Schering-Plough's current respiratory R&D pipeline
- Table 7: Forecast sales for Schering-Plough's respiratory portfolio,
2005-10
- Table 8: Schering-Plough's marketed infectious disease portfolio
- Table 9: The two key players in the hepatitis C market
- Table 10: Schering-Plough's current infectious disease R&D pipeline
- Table 11: Forecast sales for Schering-Plough's infectious disease
portfolio, 2005-10
- Table 12: Schering-Plough's marketed AIID portfolio
- Table 13: Remicade's key competitors within the AIID market
- Table 14: Schering-Plough's current AIID R&D pipeline
- Table 15: Forecast sales for Schering-Plough's AIID portfolio, 2005-10
- Table 16: Schering-Plough's marketed cardiovascular portfolio
- Table 17: Schering-Plough's current infectious disease R&D pipeline
- Table 18: Forecasts for Schering-Plough's cardiovascular portfolio,
2005-10
- Table 19: Schering-Plough's marketed oncology portfolio
- Table 20: Schering-Plough's current oncology R&D pipeline
- Table 21: Forecasts for Schering-Plough's oncology portfolio, 2005-10
- Table 22: Schering-Plough's other marketed products
- Table 23: Schering-Plough's current other R&D products
- Table 24: Forecasts for Schering-Plough's other portfolio, 2005-10
- Table 25: Breakdown of Schering-Plough's US ethical sales by therapy
area, 2004-10
- Table 26: Forecast US sales for Schering-Plough's infectious disease
portfolio, 2005-10
- Table 27: Forecast US sales for Schering-Plough's cardiovascular
portfolio, 2005-10
- Table 28: Forecast US sales for Schering-Plough's respiratory
portfolio, 2005-10
- Table 29: Forecast US sales for Schering-Plough's oncology portfolio,
2005-10
- Table 30: Forecast US sales for Schering-Plough's oncology portfolio,
2005-10
- Table 31: Forecast US sales for Schering-Plough's other portfolio,
2005-10
- Table 32: Schering-Plough's revenues by division, 2003-04
- Table 33: Schering-Plough's operating costs, 2003-04
- Table 34: Exchange rates*, 2004
- List of Figures
- Figure 1: Assessment of Schering-Plough's strategic position, 2005
- Figure 2: Competitive positioning of Schering-Plough within the
pharmaceutical market, 2004
- Figure 3: Forecast sales for Schering-Plough's major therapy areas,
2005-10
- Figure 4: Schering-Plough's level of generic threat by therapy area to
2010
- Figure 5: Schering-Plough's proportion of revenues according to
marketing strategy by therapy area to 2010
- Figure 6: Performance of Schering-Plough's business units 2001-2004
- Figure 7: Profitability of Schering-Plough's different business unit
2001-2004
- Figure 8: Change in Schering-Plough's profit margin for each of the
different business units 2001-2004
- Figure 9: Schering-Plough's six-eight year, five stage Action Agenda
- Figure 10: Development of Schering-Plough's therapeutic strategy,
2004-10
- Figure 11: Schering-Plough's business development by therapy area
- Figure 12: Schering-Plough's Total Revenues 2001-2010
- Figure 13: Schering-Plough's breakdown of corporate deals against the
industry trend between January 2004 and June 2005
- Figure 14: Schering-Plough's ethical sales breakdown 2004-10
- Figure 15: Schering-Plough's growth drivers and resistors, 2005-10
- Figure 16: Schering-Plough's licensing dependence by therapy area,
2002-2010
- Figure 17: Geographical breakdown of global sales 2001-2004
- Figure 18: Geographical breakdown of Schering-Plough's long-lived
assets 2001-2004
- Figure 19: Forecast sales for Schering-Plough's major therapy areas
2004-2010
- Figure 20: Schering-Plough's US ethical sales breakdown, 2004-10
- Figure 21: Schering-Plough's profitability stream, 2000-2004
- Figure 22: R&D and S,G&A spend and COGS as a proportion of
sales, 2004
- Figure 23: Schering-Plough's liquid assets versus total
liabilities,2000-04
- Figure 24: Benchmarking of financial strength, 2004
|
|
|
|
|
|
|
[Report]
Schering-Plough: PharmaVitae Profile 2005
Published: 2005/12
|
Published by : Datamonitor  |
|
|
Price:
|
Product Code : DC35081 |
|
|
Please inform me when related publications are released
|
|
|
View Cart
